Intracept — a minimally invasive, FDA-cleared, same-day, outpatient procedure — treats chronic vertebrogenic low back pain. It uses targeted radiofrequency energy to ablate the basivertebral nerve (BVN). This stops the nerve it from transmitting pain signals to the brain. The procedure takes approximately one hour to perform.
Minneapolis-based Relievant said in a news release that its new instruments offer more predictable and precise BVN targeting during Intracept. President and CEO Tyler Binney said the launch highlights the company’s commitment to continued innovation.
“Today, we are pleased to announce the launch of several new instruments offering greater control, precision, and ease of use during the procedure,” said Binney. “These next-generation Intracept Access Instruments are purpose-built to enhance BVN access and procedural efficiency while consistently delivering positive outcomes.”
The company designed its next-generation instruments for predictable performance across a range of bone densities. They include bevel and diamond introduced to enable consistent access with a depth marker for optimal positioning.
Additionally, Relievant designed the instruments with curved cannula assembly with its J-stylet. This enables true steerability, creating a predictable path to the BVN. Another update includes changes to the radiofrequency-delivering Intracept RF probe. It now features a flexible shaft, increasing C-arm operating clearance.
Dr. Gregory Moore claims the new instruments “raise the bar” by delivering more predictable performance. They “empower physicians” to more readily access and target the BVN. Moore serves as co-founder and partner at Pacific Sports and Spine.
